Shanghai Haohai Biological Tech Co

Shanghai Haohai Biological Tech Co

688366 · SHG · Healthcare / Biotechnology

28.61CNY-0.42 (-1.45%)

Price History

Full chart

Market Stats

Previous Close29.03
Open28.88
Day Range28.55 – 29.18
52-Week Range27.60 – 52.88
Volume488.26K
Market Cap6.81B
P/E (TTM)46.03
Forward P/E39.68
EPS0.66
Dividend Yield2.80%
Beta0.47
50-Day Avg30.71
200-Day Avg37.32

About

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in Mainland China, Europe, the United States, and internationally. The company offers ophthalmic implants, assistive devices, and medical devices; medical optical instruments, including intraocular lenses, endoscopic equipment, ophthalmic surgical instruments, and other ophthalmic medical products; hyaluronic acid and chitosan; and electronic instruments, such as semiconductors, optoelectronics, lasers, radio frequency, and ultrasonic instruments. It also engages in the research and development of biological engineering and pharmaceutical products and related technology transfer activities, consulting, and other services; research, development, production, and sales of radio frequency instruments; cell technology and biochemical product technology research and development; computer, communication, and other electronic equipment manufacturing; instrument manufacturing; manufacture and sale of biological reagents, biological agents, and biological materials; medical-grade sodium hyaluronate bio-based skincare products; intraocular lens and related products; intraocular lens injectors and materials, equipment, chemical products, and accessories for contact lenses and artificial lenses; sale of ophthalmology products; and provision of other machines and accessories. In addition, the company is involved in property management; business management consulting; non-residential real estate leasing; provision of technical services, technology promotion, development and transfer, technical consulting and exchange; wholesale of cosmetics; import and export of goods; import and export of technology; and information technology consulting services. The company was formerly known as Haohai Limited and changed its name to Shanghai Haohai Biological Technology Co., Ltd. in 2010. The company was founded in 2007 and is headquartered in Shanghai, China.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEODr. Jianying Wu
  • Employees2.00K
  • HeadquartersWenguang Building, Shanghai, China, 200336, China
  • Websitehttps://www.3healthcare.com

Leadership

  • Dr. Jianying WuGM & Chairman · b. 1964
  • Mr. Minjie Tang CPACFO & Executive Director · b. 1975
  • Ms. Yiyi ChenExecutive Director · b. 1982
  • Ms. Min TianJoint Company Secretary · b. 1989
  • Ms. Ying Tung LaiJoint Company Secretary

Financials

Income Statement

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue303.06M401.09M515.94M663.92M851.16M1.34B1.55B1.60B1.32B1.75B2.10B2.63B2.68B2.47B
Growth (%)-+32.34%+28.64%+28.68%+28.20%+58.00%+14.94%+3.21%-16.99%+32.14%+20.19%+25.27%+1.70%-7.71%
Cost of Revenue50.31M54.84M65.88M105.07M141.55M287.47M334.29M364.00M334.00M490.37M656.51M788.14M843.12M734.73M
Gross Profit252.75M346.25M450.06M558.84M709.61M1.06B1.21B1.23B990.42M1.26B1.45B1.85B1.84B1.71B
Gross Margin83.40%86.33%87.23%84.17%83.37%78.62%78.37%77.19%74.78%71.98%68.79%70.09%68.54%69.21%
Operating Expense126.92M201.06M262.61M336.23M425.63M691.72M843.01M940.48M910.74M1.08B1.29B1.48B1.49B1.49B
Operating Income125.83M145.19M187.45M222.61M283.97M365.67M368.53M291.02M79.68M176.03M155.81M368.31M347.93M220.50M
Operating Margin41.52%36.20%36.33%33.53%33.36%27.19%23.84%18.24%6.02%10.06%7.41%13.98%12.98%8.92%
EBITDA146.30M178.39M237.69M353.93M401.14M530.83M609.53M535.77M375.31M522.74M421.95M689.02M661.24M416.56M
EBITDA Margin48.27%44.48%46.07%53.31%47.13%39.47%39.43%33.58%28.34%29.87%20.06%26.15%24.68%16.84%
Net Income113.94M141.52M183.58M273.47M305.05M372.42M414.54M370.78M230.07M352.23M180.47M416.12M420.45M251.01M
Net Income Margin37.60%35.28%35.58%41.19%35.84%27.69%26.82%23.24%17.37%20.13%8.58%15.79%15.69%10.15%
R&D17.57M23.52M26.46M35.25M47.69M82.88M105.53M127.36M138.26M185.28M206.28M241.61M260.79M197.78M
R&D as % of Total Revenue5.80%5.86%5.13%5.31%5.60%6.16%6.83%7.98%10.44%10.59%9.81%9.17%9.73%8.00%
Interest Expense----216.00K2.21M3.19M4.54M4.91M4.96M7.60M7.29M18.06M18.88M
Interest Expense % of Total Revenue----0.03%0.16%0.21%0.28%0.37%0.28%0.36%0.28%0.67%0.76%

Balance Sheet

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets448.04M621.18M751.90M2.82B3.69B4.08B4.44B6.15B6.30B6.95B6.89B7.11B7.12B6.72B
Total Liabilities54.70M76.13M157.74M156.48M707.55M708.59M600.90M498.52M564.46M890.07M990.02M1.09B1.20B1.12B
Total Equity372.90M530.58M594.16M2.66B2.90B3.20B3.61B5.45B5.49B5.71B5.51B5.65B5.58B5.42B
Cash160.81M197.14M181.34M2.18B2.01B1.80B1.44B3.22B3.09B2.90B2.54B2.74B2.63B2.45B
Total Debt----26.67M37.48M36.66M49.71M108.08M105.51M118.26M407.95M448.43M398.50M
Net Debt-160.81M-197.14M-181.34M-2.18B-1.98B-1.76B-1.40B-3.17B-2.98B-2.80B-2.42B-2.33B-2.18B-2.05B

Cash Flow

Currency: CNY2012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow118.42M146.91M141.99M268.51M254.49M343.06M391.28M348.91M262.07M342.29M231.30M634.45M648.57M490.97M
Investing Cash Flow-84.29M-111.25M-88.15M-149.25M-1.51B-148.38M-794.64M-1.14B316.92M-148.09M-681.82M-376.65M282.28M-
Financing Cash Flow---70.32M1.75B-58.42M-96.48M-85.33M1.39B-190.06M-231.25M-288.35M-257.73M-390.35M-
Capital Expenditure64.63M124.36M93.64M70.11M75.67M134.71M151.87M399.30M195.86M272.10M317.15M267.23M365.49M186.94M
Free Cash Flow53.79M22.55M48.35M198.40M178.82M208.35M239.41M-50.39M66.21M70.19M-85.85M367.22M283.08M304.04M
Dividends Paid--70.32M49.68M58.56M85.78M80.02M80.02M124.04M87.91M121.89M68.52M259.86M228.74M
FCF to OCF45.43%15.35%34.05%73.89%70.27%60.73%61.19%-14.44%25.27%20.51%-37.12%57.88%43.65%61.92%
Dividend Paid to FCF--145.42%25.04%32.75%41.17%33.42%-158.81%187.34%125.25%-141.98%18.66%91.80%75.23%

Earnings

Report DateMar 26, 2020Apr 29, 2020Aug 27, 2020Oct 27, 2020Feb 26, 2021Apr 23, 2021Aug 26, 2021Oct 28, 2021Feb 28, 2022Apr 29, 2022Aug 26, 2022Oct 28, 2022Feb 27, 2023Apr 28, 2023
EPS Estimate--------------
EPS Actual0.69-0.140.300.480.660.550.760.450.240.350.060.520.110.47
Surprise--------------
TimingAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hoursAfter-hoursPre-marketAfter-hoursPre-marketAfter-hoursPre-market

Key Statistics & Ratios

Market Cap6.81B
Enterprise Value4.29B
Trailing P/E46.03
Forward P/E39.68
Price / Sales2.93
Price / Book1.28
EPS0.66
Book Value23.60
Revenue (TTM)2.32B
Gross Profit (TTM)1.55B
EBITDA310.18M
Profit Margin6.57%
Operating Margin2.49%
Return on Equity2.07%
Return on Assets1.13%
Shares Outstanding190.20M
Shares Float83.40M
Beta0.47
Dividend Yield2.80%
Dividend Rate0.85
Payout Ratio151.52%

Dividends

20231×
0.40Jul 12, 2023
20221×
0.70Aug 9, 2022
20211×
0.50Jul 29, 2021
20201×
0.70Jul 17, 2020